MiniMed is riding a wave of success, with its external insulin pump business growing 30% a year, and its continuous glucose monitor in the final stages of the FDA approval process. With so many device companies stumbling in the race to find better ways to treat diabetes, why is MiniMed flourishing?
by Wendy Diller
On the September night Nicole Johnson won the title of Miss America for 1999, she stood in front of TV...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
